Serotyping and genotyping of hepatitis C virus in Taiwanese patients with type C chronic liver disease and uraemic patients on maintenance haemodialysis

Background : To evaluate a recombinant immunoblot hepatitis C virus (HCV) serotyping assay, which determines HCV serotypes 1, 2, and 3 by detecting type‐specific antibodies to core‐and NS‐4‐derived peptides. Methods : Immunoreactivity of type‐specific antibodies among 173 chronic hepatitis C patient...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2000-07, Vol.15 (7), p.792-797
Main Authors: Yu, Ming-Lung, Wang, Liang-Yen, Chuang, Wan-Long, Dai, Chia-Yen, Sung, Ming-Hsing, Chen, Shinn-Cherng, Lin, Zu-Yau, Hsieh, Ming-Yuh, Tsai, Jung-Fa, Chang, Wen-Yu
Format: Article
Language:English
Subjects:
Biological and medical sciences
chronic hepatitis
Female
Genotype
haemodialysis
Hepacivirus - classification
Hepacivirus - genetics
Hepacivirus - immunology
Hepatitis C Antibodies - blood
hepatitis C virus
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - therapeutic use
interferon-α
Male
Medical sciences
Renal Dialysis
Sensitivity and Specificity
serotype
Serotyping
Taiwan
Tropical medicine
Uremia - blood
Uremia - therapy
Uremia - virology
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background : To evaluate a recombinant immunoblot hepatitis C virus (HCV) serotyping assay, which determines HCV serotypes 1, 2, and 3 by detecting type‐specific antibodies to core‐and NS‐4‐derived peptides. Methods : Immunoreactivity of type‐specific antibodies among 173 chronic hepatitis C patients and 43 haemodialysis patients in Taiwan was examined and the serotyping results were compared with genotyping by Okamoto’s method. Serial specimens from 29 patients undergoing interferon‐α therapy were also evaluated. Results : Of the 205 specimens for which genotyping data were available, 51.2% were of serotype 1, 31.7% of serotype 2, 1.0% of serotype 3, 2.4% of either serotype 1 or 3, and the remaining 13.7% were untypable. The serotypable rate was significantly lower in haemodialysis patients than in chronic hepatitis C patients (70.0%vs 94.9%; P < 0.001). Serotyping of genotype 2b specimens was significantly more dependent on core peptide bands than other genotypes. Using genotyping as the reference, the overall sensitivity, specificity and concordance of the recombinant immunoblot HCV serotyping assay were 86.3%, 97.2% and 83.9%, respectively. However, the serotyping assay had significantly lower sensitivity (69.2%), specificity (77.8%) and concordance (53.8%) for genotype 2b specimens. Of nine HCV complete responders, one lost type‐specific antibodies 6 months after the cessation of interferon‐α treatment. Conclusions : These results suggest that, except for less than optimal performance with immunocompromised or genotype 2b patients, the HCV serotyping assay is a practical and useful method for HCV typing in the clinical setting in Taiwan.
ISSN:0815-9319
1440-1746
DOI:10.1046/j.1440-1746.2000.02195.x